Inhibition of the PI3K/AKT signaling pathway blocks the oncogenic activity of TRIM26 in prostate cancer cells
Asian Journal of Andrology · 2026
DOI: 10.4103/aja202526 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asian Journal of Andrology, 2026. Verfasst von Yue-Ya Zhong und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Key Laboratory of Advanced Interdisciplinary Studies, the First Affiliated Hospital of Guangzhou Medical University & Guangdong Provincial Key La…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Proto-Oncogene Proteins c-akt, Ubiquitin-Protein Ligases, Tripartite Motif Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The tripartite motif-containing protein 26 (TRIM26) is an E3 ubiquitin ligase with strong oncogenic activity in various cancers. However, its role and molecular mechanism in prostate cancer (PCa) remain elusive. To clarify its role in promoting PCa progression, we evaluated TRIM26 expression in cells and clinical specimens using immunohistochemistry and found that TRIM26 was significantly upregulated in PCa tissue. Moreover, high TRIM26 levels predicted a poor prognosis in patients with PCa. Ectopic overexpression of TRIM26 increased PCa cell proliferation and migration, and this activity was suppressed by TRIM26 knockdown. Notably, TRIM26 activated both protein kinase B (AKT)/mammalian target of the rapamycin (mTOR) and the epithelial–mesenchymal transition (EMT) signaling pathways in PCa cells. Consistent with these findings, TRIM26 knockdown led to decreased activation of these signals. Furthermore, the phosphoinositide 3-kinase (PI3K)/AKT/mTOR signaling pathway activated by TRIM26 was attenuated by the PI3K inhibitor S14161. Similarly, cisplatin, a commonly used anti-PCa drug, downregulated TRIM26 and AKT/mTOR activation, while TRIM26 overexpression reversed AKT/mTOR inactivation. Finally, this finding was also demonstrated TRIM26 expression strikingly promoted tumor growth and activated AKT/mTOR signaling in a PCa xenograft. In conclusion, TRIM26 drives PCa malignancy and may be an attractive target for PCa treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Key Laboratory of Advanced Interdisciplinary Studies, the First Affiliated Hospital of Guangzhou Medical University & Guangdong Provincial Key Laboratory of Protein Modification and Disease of Guangzhou Medical Univ…
- Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China.
- Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China.
- Department of Urology, Jinling Hospital of Nanjing University, Nanjing 210002, China.
Zitieren
APA
Zhong, Y. Y., Zhang, L. H., Zhou, X. Y., Zhou, X. M., He, Y. M., Mao, X. L., & Xu, X. F. (2026). Inhibition of the PI3K/AKT signaling pathway blocks the oncogenic activity of TRIM26 in prostate cancer cells. Asian Journal of Andrology. https://doi.org/10.4103/aja202526
Vancouver
Zhong YY, Zhang LH, Zhou XY, Zhou XM, He YM, Mao XL, et al. Inhibition of the PI3K/AKT signaling pathway blocks the oncogenic activity of TRIM26 in prostate cancer cells. Asian Journal of Andrology. 2026. doi:10.4103/aja202526
BibTeX
@article{Zhong2026,
author = {Zhong, Yue-Ya and Zhang, Li-Huan and Zhou, Xin-Ye and Zhou, Xiu-Min and He, Yuan-Ming and Mao, Xin-Liang and Xu, Xiao-Feng},
title = {Inhibition of the PI3K/AKT signaling pathway blocks the oncogenic activity of TRIM26 in prostate cancer cells},
journal = {Asian Journal of Andrology},
year = {2026},
doi = {10.4103/aja202526}
}
EUVIMED